Show simple item record

dc.contributor.authorHonda, K
dc.contributor.authorKatzke, V A
dc.contributor.authorHüsing, A
dc.contributor.authorOkaya, S
dc.contributor.authorShoji, H
dc.contributor.authorOnidani, K
dc.contributor.authorOlsen, A
dc.contributor.authorTjønneland, A
dc.contributor.authorOvervad, K
dc.contributor.authorWeiderpass, E
dc.contributor.authorVineis, P
dc.contributor.authorMuller, D
dc.contributor.authorTsilidis, K K
dc.contributor.authorPalli, D
dc.contributor.authorPala, V
dc.contributor.authorTumino, R
dc.contributor.authorNaccarati, A
dc.contributor.authorPanico, S
dc.contributor.authorAleksandrova, K
dc.contributor.authorBoeing, H
dc.contributor.authorBueno-de-Mesquita, H B
dc.contributor.authorPeeters, P H
dc.contributor.authorTrichopoulou, A
dc.contributor.authorLagiou, P
dc.contributor.authorKhaw, K-T
dc.contributor.authorWareham, N J
dc.contributor.authorTravis, R C
dc.contributor.authorMerino, S
dc.contributor.authorDuell, E J
dc.contributor.authorRodríguez-Barranco, M
dc.contributor.authorChirlaque, M D
dc.contributor.authorBarricarte, A
dc.contributor.authorRebours, V
dc.contributor.authorBoutron-Ruault, M-C
dc.contributor.authorRomana Mancini, F
dc.contributor.authorBrennan, P
dc.contributor.authorScelo, G
dc.contributor.authorManjer, J
dc.contributor.authorSund, M
dc.contributor.authorÖhlund, D
dc.contributor.authorCanzian, F
dc.contributor.authorKaaks, R
dc.date.accessioned2018-11-19T13:41:24Z
dc.date.available2018-11-19T13:41:24Z
dc.date.issued2018-09-27
dc.identifier.citationCA19-9 and Apolipoprotein-A2 isoforms as detection markers for pancreatic cancer - a prospective evaluation. 2018 Int. J. Canceren
dc.identifier.issn1097-0215
dc.identifier.pmid30259989
dc.identifier.doi10.1002/ijc.31900
dc.identifier.urihttp://hdl.handle.net/10029/622256
dc.description.abstractRecently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer. This study provides a first prospective evaluation of an ApoA2 isoform ("ApoA2-ATQ/AT"), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an early detection biomarker for pancreatic cancer. We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma samples collected up to 60 months prior to diagnosis. The detection discrimination statistics were calculated for risk scores by strata of lag-time. For CA19-9, in univariate marker analyses, C-statistics to distinguish future pancreatic cancer patients from cancer-free individuals were 0.80 for plasma taken ≤6 months before diagnosis, and 0.71 for >6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and 0.65, respectively. Joint models based on ApoA2-ATQ/AT plus CA19-9 significantly improved discrimination within >6-18 months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and ≤18 months (C = 0.75 vs. 0.74, p = 0.022). At 98% specificity, and for lag times of ≤6, >6-18 or ≤18 months, sensitivities were 57%, 36% and 43% for CA19-9 combined with ApoA2-ATQ/AT, respectively, vs. 50%, 29% and 36% for CA19-9 alone. Compared to CA19-9 alone, the combination of CA19-9 and ApoA2-ATQ/AT may improve detection of pancreatic cancer up to 18 months prior to diagnosis under usual care, and may provide a useful first measure for pancreatic cancer detection prior to imaging. This article is protected by copyright. All rights reserved.
dc.language.isoenen
dc.rightsinfo:eu-repo/semantics/closedAccessen
dc.titleCA19-9 and Apolipoprotein-A2 isoforms as detection markers for pancreatic cancer - a prospective evaluation.en
dc.typeArticleen
dc.identifier.journalInt J Cancer 2018; advance online publication (ahead of print)en
html.description.abstractRecently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer. This study provides a first prospective evaluation of an ApoA2 isoform ("ApoA2-ATQ/AT"), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an early detection biomarker for pancreatic cancer. We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma samples collected up to 60 months prior to diagnosis. The detection discrimination statistics were calculated for risk scores by strata of lag-time. For CA19-9, in univariate marker analyses, C-statistics to distinguish future pancreatic cancer patients from cancer-free individuals were 0.80 for plasma taken ≤6 months before diagnosis, and 0.71 for >6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and 0.65, respectively. Joint models based on ApoA2-ATQ/AT plus CA19-9 significantly improved discrimination within >6-18 months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and ≤18 months (C = 0.75 vs. 0.74, p = 0.022). At 98% specificity, and for lag times of ≤6, >6-18 or ≤18 months, sensitivities were 57%, 36% and 43% for CA19-9 combined with ApoA2-ATQ/AT, respectively, vs. 50%, 29% and 36% for CA19-9 alone. Compared to CA19-9 alone, the combination of CA19-9 and ApoA2-ATQ/AT may improve detection of pancreatic cancer up to 18 months prior to diagnosis under usual care, and may provide a useful first measure for pancreatic cancer detection prior to imaging. This article is protected by copyright. All rights reserved.


This item appears in the following Collection(s)

Show simple item record